Advanced Bioscience Laboratories, Inc.

Advanced Bioscience Laboratories, Inc., a foreign-owned for-profit manufacturer based in Rockville, Maryland, delivers contract research, cGMP biologics manufacturing, preclinical development services, and diagnostic-support services to the National Institutes of Health as a prime contractor (99% of recent awards) with no set-aside designation. The company operates across multiple NIH institutes—primarily the National Institute of Allergy and Infectious Diseases (NIAID)—on vaccine development, HIV prevention science, pediatric formulation work, neurological therapeutics, and infectious disease countermeasures.

NIAID dominates Advanced Bioscience's customer concentration. The top five funding entities account for 91% of awards by count and 96% of combined potential value: NIAID carries 176 awards valued at $1.96 billion, followed by NIAID DEA OA Acquisitions ($213.1 million across 6 awards), the National Institute on Drug Abuse ($165.6 million across 5 awards), the National Institute of Neurological Disorders and Stroke ($154.9 million across 3 awards), and the National Cancer Institute ($95.7 million across 17 awards). The vendor has served eleven distinct customer agencies; the Army and other non-HHS agencies represent marginal activity by comparison.

Advanced Bioscience holds a portfolio of large IDIQs anchoring its delivery footprint. The Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents IDIQ carries a $364.6 million ceiling (awarded December 2021, running through November 2028); the Resources to Advance Pediatrics and HIV Prevention Science IDIQ holds $98.9 million (April 2023–April 2030) with ten recent delivery orders across pediatric formulation development, AI/machine-learning enhancement of excipient databases, bitter taste receptor blockers, quality assurance, and project management; the Manufacturing and Nonclinical Studies Support IDIQ with the National Institute of Neurological Disorders and Stroke carries $149.2 million (September 2022–September 2030); the Diagnostics Pre-Clinical Services Program IDIQ ($24 million, single-award, June 2023–June 2030) supports in vitro diagnostic development; and newer awards include an August 2024 $48.9 million IDIQ with the National Institute on Drug Abuse for pharmacology and animal model development, a May 2024 $49.7 million IDIQ for chemistry, manufacturing, and controls services, and a September 2026 $48 million vaccine manufacturing IDIQ also from NIAID. Recent representative task orders include a $6.17 million delivery order for quality assurance and quality control support under the pediatrics IDIQ (April 2023–April 2030), a $6.10 million delivery order for pharmaceutical project management (July 2024–June 2030), a $5.72 million order for lead candidate identification and pharmacology studies under the neurological disorders IDIQ (July 2024–July 2026), a $4.33 million order for expertise in the product development lifecycle including cGMP manufacturing (September 2024–August 2030), a $3.78 million order for feasibility studies on mRNA-based HIV vaccine platform development (August 2024–August 2028), and a $2.67 million order for AI/machine-learning modernization of the STEP pediatric excipient database (August 2026–July 2027).

Advanced Bioscience's award trajectory shows modest recent activity: seven awards in 2022, ten in 2023, sixteen in 2024, then one in 2025 and five in 2026 year-to-date. Sixteen awards (combined potential value $64.7 million) reach ultimate completion within the next twenty-four months, creating a recompete cliff. The vendor operates predominantly as a prime (292 of 296 awards, or 99%) and builds its own delivery teams rather than relying on subcontractors; across SCI-reportable prime contracts, subcontractors account for an average 5% share of contractor hours, with 21 named subcontractors engaged over the FY2022–FY2025 period. SCI-reported invoicing on federal service contracts above the $150,000 threshold totaled $49 million across FY2022–FY2025 (FY2022: $17.4 million across 15.5 FTEs; FY2023: $8.8 million across 4.6 FTEs; FY2024: $14.7 million across 9.8 FTEs; FY2025: $8 million across 10.1 FTEs). On federal services contracts captured in SCI, government-paid rates ranged from a 10th percentile of $231/hr through a median of $424/hr to a 90th percentile of $1,571/hr, reflecting a mix of direct labor and subcontracted effort as programs scaled. The vendor also acts as a subcontractor to the University of Illinois on federal grant awards for development of MecVax, a cross-protective subunit vaccine for enterotoxigenic E. coli (sub-awards in February 2024, July 2024, June 2025, and July 2026). Advanced Bioscience's capability portfolio centers on cGMP manufacturing, process development, analytical testing, stability studies, quality assurance, preclinical gap-filling services, animal model studies, formulation development, and project management for vaccines, therapeutics, and diagnostics across infectious disease, neurological, and pediatric disease areas.